Biologics, such as antibodies, are potentially immunogenic and may elicit anti-drug antibodies (so-called ADAs). In addition to harmful clinical manifestations such as allergy or inflammation burst, ADAs may impact the PK-PD characteristics, contributing to clearance or biological inactivation (neutralizing antibodies) of biotherapeutic agents.
At Active Biomarkers, we can evaluate ADAs on multiple platforms (Gyrolab XPlore™, MSD SQ120, conventional ELISA) according to the multi-tiered approach recommended by the regulatory guidelines.
